Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

doi:10.4239/wjd.v15.i4.724

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1557)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-8) series.

Item

Count

PDF

HTML

928

Figures (1-8)

139

Sum=1134

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

270

Sum=316

Apr 15, 2024 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Apr 15, 2024; 15(4): 724-734
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.724

Full Size Figure Download Figure

Figure 4 Teneligliptin reduced the expression of NOX4 in diabetic mice. A: mRNA of NOX-4; B: Protein of NOX-4; C: Quantitative analysis of protein expression levels for panel B. ^aP < 0.05 vs control group; ^bP < 0.05 vs streptozotocin group, n = 8. STZ: Streptozotocin.

Citation: Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes 2024; 15(4): 724-734
URL: https://www.wjgnet.com/1948-9358/full/v15/i4/724.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i4.724